The latest price target for Checkpoint Therapeutics (NASDAQ:CKPT) was reported by HC Wainwright & Co. on March 11, 2025. The analyst firm set a price target for $4.10 expecting CKPT to rise to within 12 months (a possible 2.24% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Checkpoint Therapeutics (NASDAQ:CKPT) was provided by HC Wainwright & Co., and Checkpoint Therapeutics downgraded their neutral rating.

There is no last upgrade for Checkpoint Therapeutics

The last downgrade for Checkpoint Therapeutics Inc happened on March 11, 2025 when HC Wainwright & Co. changed their price target from N/A to $4.1 for Checkpoint Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Checkpoint Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Checkpoint Therapeutics was filed on March 11, 2025 so you should expect the next rating to be made available sometime around March 11, 2026.

While ratings are subjective and will change, the latest Checkpoint Therapeutics (CKPT) rating was a downgraded with a price target of $0.00 to $4.10. The current price Checkpoint Therapeutics (CKPT) is trading at is $4.01, which is within the analyst’s predicted range.